Share Market News

Sun Pharma and Cipla’s USFDA recalls bring into the picture the rising regulatory scrutiny on Indian drugmakers. There are limited health risks, but still, the actions indicate the expectations of stricter complications. This raises concerns for pharma exporters, investors and India’s credibility in the U.S market.